Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-039992
Filing Date
2020-08-13
Accepted
2020-08-13 16:00:45
Documents
65
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q scph-10q_20200630.htm 10-Q 1331540
2 EX-31.1 scph-ex311_6.htm EX-31.1 10684
3 EX-32.1 scph-ex321_7.htm EX-32.1 8144
  Complete submission text file 0001564590-20-039992.txt   5669555

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT scph-20200630.xml EX-101.INS 1231314
5 XBRL TAXONOMY EXTENSION SCHEMA scph-20200630.xsd EX-101.SCH 47653
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE scph-20200630_cal.xml EX-101.CAL 46889
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE scph-20200630_def.xml EX-101.DEF 137956
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20200630_lab.xml EX-101.LAB 382004
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20200630_pre.xml EX-101.PRE 291187
Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38293 | Film No.: 201099187
SIC: 2834 Pharmaceutical Preparations